Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Recruiting 49Active not recruiting 23Not yet recruiting 16Completed 9Terminated 4Withdrawn 3Available 2Approved for marketing 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 28Neoplasms 26Prostatic Neoplasms 22Colorectal Neoplasms 17Head and Neck Neoplasms 14Pancreatic Neoplasms 11Lung Neoplasms 10Brain Neoplasms 10Neoplasm Metastasis 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 8Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 7Recurrence 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Lymphoma 7Glioblastoma 7Ovarian Neoplasms 6Lymphoma, Follicular 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Lymphoma, B-Cell 5Leukemia, Myeloid, Acute 5Leukemia 5Kidney Neoplasms 5Hematologic Neoplasms 5Sarcoma 4Liver Neoplasms 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Non-Muscle Invasive Bladder Neoplasms × 1 year × Clear all
NCT07551544 2026-05-19

ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

ImmunityBio, Inc.

Phase 3 Withdrawn
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07313891 2026-03-17

BOOST

Relmada Therapeutics, Inc.

Phase 3 Withdrawn
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT06816017 2025-06-16

A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Hoffmann-La Roche

Phase 1 Withdrawn
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡